EQL PHARMA AB (7JK) — Cash Flow Quality Index
EQL PHARMA AB (7JK) has a Cash Flow Quality Index of 1.37x as of December 2025. Operating cash flow of €13.44 Million exceeds net income of €9.79 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of EQL PHARMA AB to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
EQL PHARMA AB Cash Flow Quality Index (2022–2025)
Historical Cash Flow Quality Index for EQL PHARMA AB across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 7JK total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for EQL PHARMA AB (2022–2025)
Year-by-year earnings quality comparison for EQL PHARMA AB. For live market cap and the full company financial profile, see 7JK market cap overview.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.57x | €-24.65 Million | €43.12 Million | ▼ -13.5% |
| 2024 | -0.50x | €-11.44 Million | €22.70 Million | ▼ -156.4% |
| 2023 | 0.89x | €27.62 Million | €30.92 Million | ▼ -32.6% |
| 2022 | 1.33x | €41.83 Million | €31.55 Million | — |